How do you market a new biopharmaceutical product?
Build clinical understanding, make the access pathway usable, prepare the people delivering care, and support appropriate treatment beyond the first prescription.
Marketing a new biopharmaceutical product requires a coordinated plan for the approved clinical story, audience-specific education, market access, sales readiness, channel execution, and patient support. Success means the right people understand the therapy, can evaluate its benefits and risks, and can navigate appropriate treatment. Each of those steps needs its own owner and measure.
A physician can remember a brand, understand the evidence, and decide a therapy is appropriate for a patient. The patient can still leave without treatment because a benefits investigation stalled, the referral reached the wrong office, or nobody knew which specialty pharmacy could fill the prescription.
The awareness campaign may have worked. The launch still has a problem.
That is the central challenge in biopharmaceutical marketing: commercial progress depends on a sequence of decisions involving people who have different responsibilities, different information needs, and different reasons to hesitate. A brand team has to understand the entire sequence well enough to invest in the part that needs help.
This guide focuses on U.S. prescription-therapy commercialization. “Biopharma” here includes pharmaceutical and biotechnology companies launching medicines; the strategy must still change for the product, indication, regulatory pathway, and care setting.
Start with the decision the market has to make.
“Increase awareness” is too broad to guide a launch budget. Awareness among whom, of what, and to support which decision?
A specialist who already knows the mechanism may need to understand the studied population and safety profile. A community clinician may need to recognize when a referral is warranted. A health-system pharmacy committee may need operational and economic information before the product can enter its formulary process.
Begin with a market diagnosis: the current treatment pathway, unmet needs, available alternatives, evidence expectations, payer policies, diagnostic requirements, and the practical work required to initiate treatment. Include the option of continuing current care. Familiar routines compete with a new therapy even when no competing brand appears in the presentation.
Then write a commercial hypothesis precise enough to test. For example: “Among specialists treating the approved population, limited understanding of patient eligibility and uncertainty about the referral process are restricting consideration.” That statement points toward research, educational content, and workflow support. It also gives analytics something meaningful to challenge.
Validate the hypothesis with structured research across prescribers, office staff, patients, caregivers, payers, and relevant treatment sites. Sales observations are useful inputs, but the loudest anecdote should not become the national strategy. Ask what people actually do, where they abandon a process, and what evidence would change their decision.
For therapies dependent on testing, the diagnostic pathway belongs in this assessment. The connection between testing, referral, and treatment is explored further in Paper Boat Media’s diagnostics and clinical research marketing work.
The prescriber is one participant in a much larger decision.
Audience segmentation should reflect responsibility, readiness, and barriers. Two clinicians in the same specialty can need entirely different support if one treats the relevant population routinely and the other mainly refers those patients elsewhere.
Map each audience to the decision it controls and the information needed to make that decision well.
| Audience | Decision or responsibility | Useful support |
|---|---|---|
| Prescribers and referring clinicians | Evaluate clinical fit and decide whether to treat or refer. | Accurate evidence, patient-selection context, safety, administration, and referral information. |
| Nurses, pharmacists, and practice staff | Implement the treatment plan within the care setting. | Approved training, ordering steps, documentation resources, and escalation contacts. |
| Patients and caregivers | Understand options and participate in treatment decisions. | Plain-language benefits and risks, practical expectations, access information, and questions for the care team. |
| Payers and formulary committees | Assess coverage, restrictions, and value. | Appropriate clinical and economic evidence, assumptions, uncertainty, and relevant population context. |
| Health systems and treatment sites | Determine whether the organization can safely and practically deliver care. | Workflow, pharmacy, staffing, training, supply, monitoring, and financial-process information. |
| Professional and patient organizations | Serve their communities and educational missions. | Transparent collaboration with clear sponsorship, appropriate boundaries, and respect for independence. |
Researchers and investigators also need legitimate scientific exchange. Their expertise does not make them a promotional distribution list. Keep research, medical, and commercial relationships appropriate to their purpose.
The practical output is an audience plan that identifies the current barrier, the intended next step, the approved resource, and the responsible team. If the plan only specifies an email frequency, segmentation has stopped too early.
Choose a position the clinical evidence can carry.
A new mechanism can be scientifically interesting without being the strongest reason to consider a therapy. Differentiation has to connect a supported product characteristic to a relevant decision.
Start with the approved indication and available evidence. Examine efficacy endpoints, safety, study design, studied population, administration, dosing, and limitations. Identify which distinctions are meaningful, which are merely descriptive, and which require additional substantiation before they can become promotional claims.
Use a claims matrix before creative development. For each proposed statement, record the supporting source, applicable population, endpoint and time frame, necessary qualification, permitted audience and context, and review status. Include the actual chart or visual that will accompany the words.
A finding from one trial does not automatically establish superiority to a competitor evaluated in another trial. Different populations, endpoints, follow-up periods, and study designs can make a simple comparison misleading. Any comparative positioning needs an appropriate evidentiary basis and specialist review.
The central message should be understandable without relying on vague claims such as “transformative,” “revolutionary,” or “best-in-class.” Precision gives a skeptical clinician something to evaluate.
A strong position explains where the therapy fits, why that fit matters, and what the evidence does and does not support.
Visual identity has work to do here. Typography, charts, color, animation, and page hierarchy affect what people notice and remember. A risk statement technically present but visually overwhelmed by benefit imagery can still create a problematic overall impression. FDA’s drug-promotion materials discuss balance in both information and presentation.1
Approval should activate a prepared organization.
The preparation changes with the product and audience. Two more focused examples are what a rare-disease website needs before launch and how to plan oncology congress communication around a specific decision.
Commercial planning can begin well before approval. Promotional activity cannot simply move forward on the assumption that the anticipated label will arrive unchanged. Under 21 CFR 312.7, investigational drugs cannot be promoted as safe or effective for their investigational use, while legitimate scientific exchange remains recognized.2
Build scenarios for a narrower population, different safety language, a delayed decision, or an operational constraint. Identify what each scenario changes in the audience, forecast, creative, field training, and launch sequence. Materials developed against an anticipated label need reconciliation with the final approved labeling before release.
Unbranded disease education also deserves review. Omitting a product name does not, by itself, settle whether the overall communication is promotional. Assess the content, context, links, targeting, and relationship to other company activity.
| Gate | What should be ready | What could change the decision |
|---|---|---|
| Market preparation | Audience research, journey mapping, internal planning, and appropriately governed education. | New evidence, revised assumptions, regulatory developments, or an unresolved promotional boundary. |
| Approval and label reconciliation | Final claims, risk presentation, revised assets, field certification, and regulatory submission planning. | Label differences, unresolved review findings, or incomplete training. |
| Operational release | Supply and distribution confirmation, working support processes, tested digital resources, and accountable owners. | Unavailable product, broken enrollment, insufficient site capacity, or a material customer-service gap. |
| Early launch expansion | Evidence that intended audiences understand the offer and can complete the relevant next steps. | Access friction, misinformation, a safety update, or demand exceeding operational capacity. |
Regulatory should establish the applicable submission process and timing. Internal medical, legal, and regulatory approval is distinct from an FDA submission or advisory review. Product category and approval pathway matter; accelerated-approval products have specific promotional-material submission requirements.3
Readiness should be demonstrated through a rehearsal. Have someone unfamiliar with the build find the correct resource, request assistance, and follow a simulated referral or support case through every handoff. A slide marked “complete” tells you less than a process that works.
A prescription is the beginning of another process.
Market Access belongs in brand planning from the beginning. Coverage, restrictions, affordability, specialty distribution, and site-of-care requirements can determine whether clinical interest produces a treatment start.
Map the practical sequence for this particular therapy. It may include diagnosis, specialist referral, eligibility assessment, benefits investigation, prior authorization, prescription routing, scheduling, dispensing, administration, and follow-up. Identify where the manufacturer can appropriately provide information or support and where the decision belongs to the payer, provider, or patient.
Ask Market Access to distinguish nominal coverage from usable access. A coverage percentage can hide restrictions, exclusions, documentation requirements, and differences between the medical and pharmacy benefit. An access claim should identify the population, source, date, and relevant limitations.
Payer communication requires its own evidentiary and regulatory approach. Clinical outcomes, resource use, budget impact, and uncertainty may matter differently to a formulary committee than to a patient. FDA addresses these communications separately. Its June 2026 revised guidance is a draft, explicitly marked not for implementation; teams should distinguish that proposal from the currently applicable framework.4
Support materials should explain verified processes clearly without promising coverage, reimbursement, a particular out-of-pocket cost, or eligibility that has not been established. Manufacturer copayment programs and other assistance arrangements need specific compliance controls. OIG has identified risks when manufacturer coupons induce purchases paid for by federal healthcare programs.5
When access is the obstacle, the next useful marketing investment may be a clearer process and a better handoff.
Give every channel a job in the decision process.
Omnichannel marketing coordinates relevant experiences across channels. The important question is what a person needs next and whether the organization can respond without repetition, contradiction, or an inappropriate use of data.
Consider a hypothetical specialist who attends a congress and requests approved administration information. With the necessary permissions, the follow-up could provide that resource, offer a relevant field conversation, and point practice staff toward operational support. If the clinician submits a medical-information request, the appropriate medical process should handle it. The customer should not have to re-explain the same issue at every step.
Start with a small number of journeys the team can execute reliably. For each, document the trigger, audience, purpose, approved content, permission requirements, next action, owner, and suppression rules. A suppression rule might prevent duplicate outreach or halt promotion while a contact preference is being resolved.
The website should answer the next serious question.
A healthcare professional may need the prescribing information, study details, administration resources, or a representative contact. A patient may need plain-language education and a way to discuss questions with the care team. Access staff may need current support forms. Distinct pathways can serve those needs without forcing every visitor through the same landing page.
Search and AI visibility benefit from clear, accessible, well-maintained source material: descriptive headings, readable HTML, dated references, accurate terminology, and content that keeps important qualifications close to the claim. These are sensible discoverability practices, not a guarantee that an AI system will cite or accurately summarize the product. Monitor actual answers for omissions and errors.
Choose paid media by audience and message fit.
Professional publishers, search, contextual placements, field-supported email, and other channels should be evaluated against qualified reach and the ability to communicate responsibly. A crowded channel mix can consume budget while making coordination harder.
Short formats require deliberate review. FDA’s character-limited social-media guidance remains a draft; its discussion of benefit and risk presentation does not create a blanket exemption for small ads. The final rule for qualifying DTC television and radio advertisements separately requires the major statement to be clear, conspicuous, and neutral.67
Keep privacy, consent, data permissions, vendor contracts, and platform policies in the channel design. Treat patient-support information as sensitive operational data. Do not assume it can be repurposed for advertising because the same company operates both programs.
Equip the field for the questions that actually arise.
Sales readiness requires more than familiarity with a core visual aid. Representatives need to understand the approved story, its limits, the clinical setting, and the next responsible action when a question falls outside their role.
Build the field toolkit around real encounters: a clinician questioning the study population, an office confused about enrollment, a pharmacist asking about product handling, or a patient-related issue requiring escalation. Use approved responses and role-specific routing. Medical questions, adverse events, and product complaints need their designated processes.
Training should include practice and assessment. Can the representative explain the evidence accurately without reading the slide? Can they recognize when to refer a question? Can they find the current resource and avoid an obsolete version? Can a manager coach those behaviors consistently?
Give congress participation a purpose beyond attendance.
For each congress, define the relevant audience, legitimate educational or promotional purpose, permitted engagement, and follow-up owner. Plan promotional exhibits and Medical Affairs activities with appropriate separation and clear roles. Scientific presentations, commercial exhibits, advisory work, and independent education are different activities even when they occur in the same hotel.
Engage external experts for genuine needs and relevant expertise. The PhRMA Code is a voluntary industry code, distinct from legal requirements, and places patient welfare and professional clinical judgment at the center of HCP interactions. OIG also maintains a specific fraud alert on speaker programs.89
Measure the quality of the questions, the usefulness of the interaction, and completion of appropriate follow-up. A badge scan alone says very little about whether the meeting helped anyone make a better decision.
Coordination needs owners, authority, and working rules.
The marketing leader should translate corporate objectives into a small set of brand priorities and explain how each investment supports them. “Grow the brand” needs to become specific decisions about audiences, barriers, capabilities, and resource allocation.
Cross-functional alignment works when decision rights are explicit. Marketing can own positioning and campaign priorities while qualified partners retain responsibility for medical, regulatory, legal, privacy, safety, access, and operational decisions in their disciplines.
| Function | Contribution to the launch | Interface to define |
|---|---|---|
| Marketing and Sales | Brand priorities, audience strategy, approved promotional execution, field insights, and training. | Who updates materials and resolves recurring field barriers? |
| Medical Affairs | Scientific expertise, medical education, evidence context, and medical-information processes. | How are requests routed while preserving appropriate medical independence? |
| Market Access | Payer understanding, value communication, and access strategy. | Who validates access claims and communicates policy changes? |
| Commercial Operations and Analytics | Customer systems, permissions, measurement, data quality, and deployment. | Who verifies that targeting, handoffs, and reporting work? |
| Regulatory, Legal, and Compliance | Claim assessment, promotional review, legal requirements, and relevant codes. | Who has release authority and how are changes controlled? |
| Safety, Quality, and Supply | Safety reporting, product complaints, availability, and operational constraints. | How does an issue reach the right owner and alter commercial activity? |
| Corporate Communications | Corporate narrative, media response, milestone communication, and reputation. | How do public statements stay consistent with evidence and regulatory status? |
Medical, legal, and regulatory review should begin with the brief. Agree on audience, purpose, sources, claim boundaries, risk presentation, and channel before investing heavily in production. Maintain version control, approval records, expiration rules, and a way to withdraw or replace assets across agencies and platforms.
For CDER-regulated prescription drugs, OPDP is a central promotional oversight office. CBER has its own advertising and promotional labeling function for products under its jurisdiction. Establish the correct pathway for the asset.103
Hiring and agency management should follow the capability gaps. A first-launch team may need experienced review operations, analytics, field enablement, and access coordination before it needs another creative vendor. Evaluate staff and partners on strategic judgment, scientific accuracy, collaboration, execution quality, and demonstrated learning. Give every agency a defined scope, deliverables, accountable owner, and change-control process.
AI can assist with internal organization or draft development in an approved environment. It should not independently invent claims, answer patient-specific medical questions, or release promotional variants. Generated content needs source verification and the same applicable review controls as other content.
Sustained utilization has to remain clinically appropriate.
Appropriate initiation and continuation deserve separate plans. The barriers change once a patient begins treatment: practical instructions, appointments, financial changes, side effects, follow-up, or confusion about whom to contact.
Patient support should help people understand the care plan and reach the right professional. Depending on the therapy, this may include reviewed onboarding resources, reminders with consent, administration education, logistical assistance, or navigation of eligible support services. The care team retains responsibility for individual treatment decisions.
A discontinuation is not automatically a marketing failure. Treatment may end because the course is complete, benefit is inadequate, an adverse event occurs, the clinician changes therapy, or the patient makes an informed choice. A continuation program should help identify and resolve avoidable obstacles without pressuring people to remain on an unsuitable treatment.
For an ongoing therapy, persistence measures may be useful with clear definitions and clinical context. For a one-time therapy, repeat utilization may be the wrong concept entirely. Follow-up completion, monitoring, or the performance of the referral and treatment pathway may be more relevant.
Listen for the reasons behind the numbers through appropriately governed research and operational reporting. Distinguish affordability problems from clinical decisions and unknown outcomes. A missing refill record is a signal to investigate, not proof of nonadherence.
Measure the point where progress stops.
A useful measurement system connects activity to decisions while acknowledging what the data cannot prove. Set definitions, denominators, observation windows, and sources before launch. Otherwise teams can report impressive numbers that describe different things.
| Stage | Useful indicators | Interpretation to avoid |
|---|---|---|
| Awareness | Qualified audience reach and researched recognition or message understanding. | Treating raw impressions as evidence of clinical comprehension. |
| Engagement | Relevant resource use, requested follow-up, and resolved information needs. | Assuming time on page or email opens establish intent. |
| Adoption | Appropriate initial prescribing, account readiness, referrals, and verified treatment starts. | Counting a written prescription as completed treatment initiation. |
| Access | Process completion, time to start, unresolved cases, and documented barriers. | Presenting nominal coverage as frictionless access. |
| Continued use | Therapy-appropriate follow-up, persistence where relevant, and documented reasons for stopping. | Assuming every discontinuation was avoidable or inappropriate. |
| Commercial impact | Net revenue, spend, forecast performance, and credible estimates of incremental contribution. | Assigning every sale after an exposure to the campaign. |
Use shared reporting to guide investment. If understanding is weak among relevant clinicians, improve the evidence communication. If understanding and prescribing intent are strong but starts lag, inspect access and operational barriers. If eligible patients cannot reach a treatment site, another awareness campaign may add demand to an already constrained process.
Where feasible, use appropriately designed holdouts, matched comparisons, or phased deployments to estimate incremental impact. Account for differences in access, field coverage, competition, patient mix, and data lag. Observational marketing data require caution about causality.
Budget in scenarios rather than a single optimistic forecast. Identify launch-critical commitments, adjustable media, research and testing funds, and a contingency reserve. Include review, content updates, privacy and data work, and customer support in the cost of execution.
Return on investment should use incremental contribution and attributable program cost where defensible. Revenue divided by advertising spend is a different measure. When evidence is insufficient to estimate incremental return, report that limitation and use the best available intermediate indicators without relabeling them as ROI.
The dashboard looks healthy. Treatment starts do not.
Four different next steps.Fictional teaching figures. These are case statuses, not final conversion rates.
Illustrative scenario: The following numbers are fictional teaching figures, not a client result or industry benchmark.
A newly launched specialty therapy has strong engagement among its intended HCP audience. The field reports constructive conversations. Yet starts are below the operating plan.
The team examines a defined cohort of 100 eligible referrals received during one period and checks their status at a fixed follow-up date. Forty-five have started treatment. Thirty are waiting for missing documentation, 15 are awaiting a payer decision, and 10 have not yet received a treatment-site appointment.
Those categories describe status at the observation date. They do not establish permanent abandonment, clinical suitability beyond the stated referral eligibility, or the final conversion rate. Some cases may progress later.
Nevertheless, the pattern gives the team a practical next investigation. It reviews the documentation requirements and finds that practices are using inconsistent instructions. It also checks whether appointment delays reflect limited capacity, referral-routing errors, or a scheduling communication gap.
The response could include clearer reviewed documentation resources, better staff training, corrected handoffs, and coordination with appropriate operational owners. Marketing can help communicate the process; it cannot override payer decisions or create treatment capacity through copywriting.
For the next comparable cohort, the team tracks incomplete submissions, time spent at each stage, and treatment starts after the same follow-up window. It also checks for changes in patient mix, coverage, and capacity before attributing improvement to the intervention.
This is the value of connecting marketing to launch operations: the organization can distinguish a message that failed from a process that prevented an informed decision from becoming treatment.
The brand plan has to change when the evidence or market changes.
Annual brand planning should revisit the commercial hypothesis. Review new evidence, safety developments, approved labeling, treatment guidelines, access conditions, competition, patient experience, and the performance of the care pathway. Define which changes justify a strategy revision between annual planning cycles.
A competitor’s new indication may change consideration. A payer restriction may reduce practical access. A formulation change may alter administration education. A new guideline may change where clinicians consider a therapy, but it does not itself expand the FDA-approved indication.
Lifecycle opportunities can include new indications, formulations, delivery approaches, populations, or supporting evidence. Each has its own development, regulatory, medical, and commercial requirements. Future possibilities should not enter current promotional messaging as though they were already established.
Real-world evidence can help answer questions about use in practice, subject to study quality and appropriate interpretation. It does not automatically establish causality or support every desired comparative claim. Review the population, methods, confounding, limitations, and permitted communication context.
Manage the practical consequences of change. Retire old claims, update sales tools, revise access information, retrain affected teams, and check that agencies and media partners have deployed the correct versions. Mature brands need this discipline as much as launch brands.
For companies managing several assets or business models, the broader life-sciences marketing strategy should connect the portfolio while preserving the specific evidence and audience needs of each product.
Can the organization demonstrate these eight things?
Use these questions in a launch review. Request an artifact, a working demonstration, or a named owner for each answer.
- A clear clinical position. The team can explain the relevant population, supported benefit-risk story, and evidence limitations in language the audience understands.
- An audience plan tied to decisions. Each priority audience has a defined barrier, appropriate resource, intended next step, and responsible team.
- A reconciled launch package. Claims, creative, training, and channel execution match the final label and required review and submission processes.
- A usable access pathway. Someone has tested the customer-facing steps, confirmed the support responsibilities, and identified unresolved dependencies.
- A field team prepared for boundaries. Representatives can explain approved information and correctly route medical questions, safety reports, and other requests.
- A controlled customer experience. Permissions, contact preferences, data use, content versions, and follow-up ownership work across the selected channels.
- A measurement plan that identifies barriers. Definitions and observation windows distinguish attention, intent, access, initiation, and appropriate continuation.
- A response plan for change. The organization knows who can stop activity, reallocate funds, withdraw materials, and coordinate an urgent update.
When an answer is weak, assign an owner and a decision date. The launch review should produce an operating plan that leadership can act on.
Questions biopharma leaders ask before launch.
When should marketing planning begin?
Begin early enough to inform research, positioning, access planning, capability development, and internal readiness. The timing depends on development risk and product complexity. Distinguish preparation from external promotion of an investigational product; the latter is constrained by the applicable rules.2
What is the difference between brand strategy and a launch plan?
Brand strategy defines the intended position, priority audiences, supported differentiation, and commercial choices. The launch plan specifies the work, owners, dependencies, resources, release decisions, and measurements needed to put that strategy into practice.
Does every new therapy need consumer advertising?
No. Channel selection should follow the patient population, care pathway, evidence, access conditions, and research. A specialist-led or complex therapy may require more attention to referrals, practice readiness, and professional education than broad consumer media.
How should Marketing and Medical Affairs work together?
Coordinate around accurate science, relevant information needs, and well-defined handoffs. Preserve the appropriate independence and responsibilities of medical activities. Do not treat medical inquiry handling or scientific relationships as another sales activation tactic.
What does sustained utilization mean?
It means supporting treatment over the clinically appropriate period, with the patient’s care team guiding decisions. The measure depends on the therapy. It may involve persistence for an ongoing medication or appropriate monitoring after a one-time treatment.
How much should a biopharmaceutical launch spend on marketing?
There is no useful universal amount or percentage. Build the budget from the addressable population, audience concentration, access barriers, launch capabilities, field model, channel costs, operational capacity, and the investment needed to resolve the most important uncertainties.
How do you know whether the strategy is working?
Look for evidence that the intended audience understands the therapy, unresolved questions receive appropriate answers, access processes improve, and suitable patients can begin and continue treatment as directed. Pair those indicators with commercial results and a credible assessment of what marketing contributed.
What should an outside marketing partner contribute?
Clear commercial diagnosis, audience research, positioning, content and channel strategy, coordinated execution, and accountable measurement. Qualified medical, regulatory, legal, safety, privacy, and access specialists should retain responsibility for their disciplines.
Where is your next launch most likely to stall?
I help leadership teams examine the commercial decisions behind the marketing plan: who needs to understand the product, which barrier deserves investment, and how the message, channel, and operating process should work together.
For launch planning, positioning, and commercial marketing support, explore my pharmaceutical marketing consulting or bring the specific challenge to a conversation.
Discuss a biopharma marketing challengeSources and regulatory references
Sources checked October 7, 2026. This article provides a commercial planning framework; product-specific execution requires the responsible medical, regulatory, legal, compliance, and safety teams. Draft guidance, final guidance, regulations, and voluntary codes have different status.
- FDA: Drug Promotion. Presentation of risk and efficacy information and fair balance.
- 21 CFR 312.7: Promotion of investigational drugs. Preapproval promotional restrictions and scientific exchange.
- FDA: Submitting Biologics Advertising & Promotional Labeling. CBER review, submissions, and accelerated-approval materials.
- FDA: Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities. June 2026 revised draft, not for implementation. See also the June 2018 final guidance.
- HHS OIG: Manufacturer Safeguards May Not Prevent Copayment Coupon Use for Part D Drugs. Risks and safeguards relating to manufacturer coupons.
- FDA: Internet/Social Media Platforms with Character Space Limitations. June 2014 draft guidance, not for implementation.
- FDA: Clear, Conspicuous, and Neutral Major Statement Final Rule Questions and Answers. Final guidance concerning qualifying DTC television and radio advertisements.
- PhRMA: Code on Interactions With Health Care Professionals. Voluntary industry code; current linked version effective January 1, 2022.
- HHS OIG: Special Fraud Alerts, Bulletins, and Other Guidance. Includes the November 16, 2020 speaker-program fraud alert.
- FDA: Office of Prescription Drug Promotion. Mission and promotional oversight responsibilities.
